While anti-IL-5 treatment has been widely approved for treating eosinophilic asthma, attenuation of broad-range inflammatory and physiological changes after allergen challenge suggests that blocking CCR3, IL-3, and GM-CSF are also important targets for the management of allergic asthma. Here, CCR3 is linked to allergic asthma.